PubHawk
J Neurochem September 2024 PMID 38019032

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review.

James J Gattuso, Carey Wilson, Anthony J Hannan, Thibault Renoir

Full text PDF Download social card

Mentions

28
Peak: 17 in Dec 2023
across 3 sources since Nov 2023

Extended reach

101,880
potential audience

Total likes

60

Video views

933

Mentions per month

Nov 2023 – Mar 2025

Where it's discussed

  • X / Twitter20 posts
  • News6 articles
  • YouTube2 videos

AI synopsis

What people are saying

The overall tone reflects cautious optimism about psilocybin's therapeutic possibilities, with discussions referencing the systematic review and questioning its mechanisms, such as 'What are shrooms doing to your brain?', demonstrating a moderate level of engagement and curiosity about the scientific implications.

AgreementModerate agreement

Most discussions acknowledge the potential benefits of psilocybin, indicating general agreement on its therapeutic promise, though some mention that it is still not fully understood.

InterestModerate interest

The topics seem to attract moderate curiosity, with posts referencing the scientific review and potential medical benefits, but lacking deeply passionate or speculative tone.

EngagementModerate engagement

Postings include mentions of the systematic review and related questions like 'What are shrooms doing to your brain?', showing some effort to understand or explore the research, but not extensive debate or critique.

ImpactModerate impact

The discussions highlight the importance of psilocybin research for mental health, suggesting a recognition of its potential significance, though they do not claim immediate revolutionary change.

Top posts

Most liked on X and Bluesky
Agingdoc
@agingdoc1 · X

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review https://t.co/8qNPnA2QKa @APRAresearch https://t.co/Ug3x2Cbc7t

Dec 16, 2023 · 12 likes · 2 shares · 42,374 followers View post →
eksogen
@eksogenisk · X

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review https://t.co/kNkvOG5T6f

Dec 4, 2023 · 9 likes · 5 shares · 1,946 followers View post →
BrainEnergyMetabolism
@BrainMetabolism · X

What are shrooms doing to your brain? Systematic review of #Psilocybin as a lead therapeutic candidate in psychiatric disorders. @anthonyjhannan #mentalhealth #depression https://t.co/vAteUgdYCb https://t.co/HInqpEG4MY

Nov 30, 2023 · 6 likes · 1 share · 1,254 followers View post →
john morley
@drjohnmorley · X

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review - Gattuso - Journal of Neurochemistry - Wiley Online Library https://t.co/IOKYLk6KFB

Dec 16, 2023 · 4 likes · 1 share · 8,304 followers View post →
eksogen
@eksogenisk · X

https://t.co/gmKT14ChVn

Dec 4, 2023 · 3 likes · 3 shares · 1,946 followers View post →
Stilgherrian
@stilgherrian · X

Psilocybin has treatment potential for a range of psychiatric conditions but remains poorly understood” https://t.co/n1fUJrfqsb Full paper: https://t.co/RFkVXw7ncS

Dec 15, 2023 · 2 likes · 1 share · 19,125 followers View post →

All mentions

Nico.
@Nicolas_Lupo · X

RT @agingdoc1: Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review ht…

Jan 9, 2024 · 2 shares · 712 followers View post →
Mind Your Science!
@MindYourSci · X

RT @agingdoc1: Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review ht…

Dec 17, 2023 · 2 shares · 132 followers View post →
john morley
@drjohnmorley · X

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review - Gattuso - Journal of Neurochemistry - Wiley Online Library https://t.co/IOKYLk6KFB

Dec 16, 2023 · 4 likes · 1 share · 8,304 followers View post →
Agingdoc
@agingdoc1 · X

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review https://t.co/8qNPnA2QKa @APRAresearch https://t.co/Ug3x2Cbc7t

Dec 16, 2023 · 12 likes · 2 shares · 42,374 followers View post →
Gay Rainbow Anarchist
@_manin_black_ · X

RT @stilgherrian: Psilocybin has treatment potential for a range of psychiatric conditions but remains poorly understood” https://t.co/n1fU…

Dec 15, 2023 · 1 share · 2,991 followers View post →
Stilgherrian
@stilgherrian · X

Psilocybin has treatment potential for a range of psychiatric conditions but remains poorly understood” https://t.co/n1fUJrfqsb Full paper: https://t.co/RFkVXw7ncS

Dec 15, 2023 · 2 likes · 1 share · 19,125 followers View post →
Gaetano Lardieri
@EntheoG108 · X

https://t.co/En7X5Zkn6t

Dec 12, 2023 · 168 followers View post →
Michael Mindrum, MD
@MichaelMindrum · X

RT @BrainMetabolism: What are shrooms doing to your brain? Systematic review of #Psilocybin as a lead therapeutic candidate in psychiatric…

Dec 8, 2023 · 1 share · 9,893 followers View post →
tolstoj_enjoyer
@Tolstoj_Enjoyer · X

RT @eksogenisk: Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review

Dec 5, 2023 · 5 shares · 303 followers View post →
Seretoninen
@JTFS84 · X

RT @eksogenisk: https://t.co/gmKT14ChVn

Dec 5, 2023 · 3 shares · 996 followers View post →
Seretoninen
@JTFS84 · X

RT @eksogenisk: Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review

Dec 5, 2023 · 5 shares · 996 followers View post →
Johnny Alpha tc.
@jhlrsn · X

RT @eksogenisk: Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review

Dec 4, 2023 · 5 shares · 2,640 followers View post →
Bengt Erixon
@bengt_erixon · X

RT @eksogenisk: Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review

Dec 4, 2023 · 5 shares · 1,013 followers View post →
Bengt Erixon
@bengt_erixon · X

RT @eksogenisk: https://t.co/gmKT14ChVn

Dec 4, 2023 · 3 shares · 1,013 followers View post →
Kenneth Maarud
@MaarudKenneth · X

RT @eksogenisk: Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review

Dec 4, 2023 · 5 shares · 518 followers View post →
Kenneth Maarud
@MaarudKenneth · X

RT @eksogenisk: https://t.co/gmKT14ChVn

Dec 4, 2023 · 3 shares · 518 followers View post →
eksogen
@eksogenisk · X

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review https://t.co/kNkvOG5T6f

Dec 4, 2023 · 9 likes · 5 shares · 1,946 followers View post →
eksogen
@eksogenisk · X

https://t.co/gmKT14ChVn

Dec 4, 2023 · 3 likes · 3 shares · 1,946 followers View post →
BrainEnergyMetabolism
@BrainMetabolism · X

What are shrooms doing to your brain? Systematic review of #Psilocybin as a lead therapeutic candidate in psychiatric disorders. @anthonyjhannan #mentalhealth #depression https://t.co/vAteUgdYCb https://t.co/HInqpEG4MY

Nov 30, 2023 · 6 likes · 1 share · 1,254 followers View post →
Amsterdam Psychedelic Research Association (APRA)
@APRAresearch · X

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review https://t.co/xT18iQulq0

Nov 29, 2023 · 2 likes · 4,000 followers View post →